Nutrition Business Journal

GSK's Alli Yet to Achieve Blockbuster Status in U.S. Weight-Loss Market

News of OTC drug’s unpleasant side effects may be helping to hinder sales

Alli, the over-the-counter (OTC) weight-loss drug launched in June 2007 by GlaxoSmithKline (GSK), was predicted to become an overnight success, with GSK pumping $150 milli

All access premium subscription

This content requires a subscription to Nutrition Business Journal.

As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.

Email [email protected] for more information about subscribing.